In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on MannKind (MNKD), with a price target of $6.00. The company’s shares closed last Thursday at $4.19.
According to TipRanks.com, Livnat is a 5-star analyst with an average return of 14.6% and a 54.5% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Taiwan Liposome Company, and Verrica Pharmaceuticals.
MannKind has an analyst consensus of Strong Buy, with a price target consensus of $6.60, representing a 67.1% upside. In a report issued on March 18, Oppenheimer also assigned a Buy rating to the stock with a $7.00 price target.
See today’s analyst top recommended stocks >>
Based on MannKind’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $18.44 million and GAAP net loss of $26.41 million. In comparison, last year the company earned revenue of $15.99 million and had a GAAP net loss of $14.26 million.
Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of MNKD in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MannKind Corp. is a biopharmaceutical company. It focuses on the discovery, development and, commercialization of therapeutic products for diseases, such as diabetes and cancer. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Westlake Village, CA.